Views & Analysis | Perspectives on pharma industry issues

Market Access

Two business hands outstretched, one weighing cash, the other drugs, for balance

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Digital

IQVIA Technologies sponsored podcast, with Updesh Dosanjh

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Digital

Two female silhouettes in a city office overlook the urban landscape below

How female leadership can benefit industry

Day One Strategy’s founding partners Abigail Stuart and Hannah Mann share the benefits female leadership can bring to industry.

Patients

Maintenance: The underexamined half of the GLP-1 story

GLP-1 treatments have historically had an exit problem, as appetite suppression stops when the medication stops.

Oncology

pharmaphorum podcast Episode 276, Irina Babina, Concr

Getting predictive technologies to patients, with Concr

Dr Irina Babina, CEO of oncology R&D platform Concr, discusses how current regulatory frameworks were built for static diagnostics.

Articles

“Doctors 2.0 & You”…and Me!

We get an insight into “Doctors 2.0 & You”, held recently in Paris by speaker from the event, Ángel González. On 23rd – 24th May 2012, the second “Doctors 2.0 & You” event was held in the city of Paris. The event was organized by Denise Silber, thought leader in the healthcare social media...

Articles

The back to basics series: part 1 – how health content finds...

Fard Johnmar starts his new series by encouraging health marketers to take a people-first approach toward digital and working to understand the fundamental drivers of online health content consumption. It’s enough to drive you crazy. What is it? Digital! Don’t believe me? Take a look at the graphic developed by the investment banking firm...

Articles

Medical devices: the future is emerging markets

Following our emerging markets focus, Jim Furniss provides thoughts on the opportunities and challenges for the device market. The healthcare industry has recognised for a number of years that there is a great untapped potential in emerging markets...

Sales & Marketing

Accelerating growth through strategic investment in healthca...

CEVA FORPATIENTS at Rockingham, UK will offer the healthcare supply chain a new, sustainably designed multi-user site.

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Digital

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Digital

How female leadership can benefit industry

Day One Strategy’s founding partners Abigail Stuart and Hannah Mann share the benefits female leadership can bring to industry.

Market Access

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.